Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDA

Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc.

Read more at prnewswire.com